{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Participants who died from treatment-related complications from the time of ASCT.","groups":[{"description":"Patients with refractory or relapsed myeloma received high-dose GemBuMel with ASCT","id":"OG000","title":"Gemcitabine/Busulfan/Melphalan"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From date of transplant until the date of death from treatment-related complications, assessed up to 2 years","title":"Percent of Participants Dying From Treatment-Related Complications","type":"SECONDARY","unitOfMeasure":"Participants"}